Head-to-head evidence
amycretin vs HDG1901
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
amycretin
Developed by Novo Nordisk
NCT06542874 · Phase 2 · completed
This was a randomized, quadruple-blinded, placebo-controlled trial with 448 participants and a validated diabetes disease-control endpoint (HbA1c). The primary comparison was clearly positive, with HbA1c reductions of up to 1.8 percentage points (subcutaneous) and 1.5 points (oral) that were statistically significant against placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2028 · NCT07400107 (registry estimate)
HDG1901
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
NCT06739044 · Phase 3 · completed
The trial randomized 494 participants to HDG1901 or active Ozempic treatment, but neither participants nor investigators were blinded. Its primary endpoint was change in HbA1c, a surrogate measure, and the registry does not report whether the comparison met its objective, supporting a moderate evidence grade.
Caveat: source is secondary industry coverage that does not cite the trial registry number; attribution rests on sponsor/program match only.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amycretin's landscape · HDG1901's landscape